title: Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study.
abstract: Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through theRare Cancer Network(RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors.
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA; Department of Radiation Oncology, Acibadem Adana Hospital, Acibadem University, Adana, Turkey.
authors.forename: Gamze
authors.initials: G
authors.lastname: Ugurluer
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester , MN, USA.
authors.forename: Robert C
authors.initials: RC
authors.lastname: Miller
authors.affiliation: Department of Radiation Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, China.
authors.forename: Yexiong
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Center Antoine-Lacassagne , Nice, France.
authors.forename: Juliette
authors.initials: J
authors.lastname: Thariat
authors.affiliation: Department of Radiation Oncology, Berlin Inselspital, Bern University Hospital and University of Bern, Charité Universitätsmedizin Berlin , Germany.
authors.forename: Pirus
authors.initials: P
authors.lastname: Ghadjar
authors.affiliation: Department of Radiation Oncology, University Hospital , Brest, France.
authors.forename: Ulrike
authors.initials: U
authors.lastname: Schick
authors.affiliation: Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne , Lausanne, Switzerland.
authors.forename: Mahmut
authors.initials: M
authors.lastname: Ozsahin
keywords: Non-Hodgkin’s lymphoma; chemotherapy; primary hepatic lymphoma